Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26842234.
- Also identified by DOI 10.1158/1078-0432.CCR-15-3054 and PMC identifier 4818736.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.
Medical subject headings
- Precision Medicine
- Xenograft Model Antitumor Assays